Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-08-27 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
监事会关于公司第三期限制性股票激励计划相关事项的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion regarding the repurchase and cancellation of restricted shares under the company's third restricted stock incentive plan. It discusses the approval and verification of the repurchase and cancellation of restricted stock, including specific prices and quantities. This is a regulatory announcement related to share repurchase and cancellation under an incentive plan, not a full financial report or earnings release. It is not a report publication announcement or a certification. The content fits best under Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2024-08-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 11th meeting of the 8th Supervisory Board of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes the approval of the company's 2024 semi-annual report and a proposal regarding the repurchase and cancellation of restricted shares. The document is short (929 characters) and primarily serves as a formal announcement of meeting decisions rather than containing the full semi-annual report or detailed financial data. It also references other announcements for detailed information. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not contain the full interim report itself but announces supervisory board resolutions and related corporate actions.
2024-08-27 Chinese
中国国际金融股份有限公司关于安徽安科生物工程（集团）股份有限公司第三期激励计划回购注销部分限制性股票相关事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the company's third restricted stock incentive plan and the repurchase and cancellation of some restricted stocks. It contains detailed explanations about the stock incentive plan, approval procedures, repurchase reasons, prices, and financial advisor opinions. The document is not a general annual or quarterly report, nor is it a simple announcement. It is a specialized advisory report related to capital/financing activities, specifically stock repurchase and cancellation under an incentive plan. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (5716 characters) and detailed content support this classification with high confidence.
2024-08-27 Chinese
2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the period ending June 2024. It includes financial figures and relationships between the company and related parties. The document is relatively short (1616 characters) and appears to be a specific financial disclosure related to related party transactions rather than a full financial report or announcement. It does not contain comprehensive financial statements or management discussion, nor does it announce a report publication. It is a regulatory disclosure about related party transactions, which typically falls under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Interim Report, or Audit Report. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-27 Chinese
关于回购注销部分限制性股票减资暨通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the repurchase and cancellation of part of restricted shares, which leads to a reduction in registered capital. It includes details about notifying creditors and the procedures for debt claims. The content focuses on share repurchase and capital reduction, not on financial results, management changes, or regulatory certifications. The key phrase is '回购注销部分限制性股票减资暨通知债权人的公告' which translates to 'Announcement on repurchase and cancellation of part of restricted shares and notification to creditors.' This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or share cancellations. The document length is short (1467 characters), but it contains substantive information about the transaction itself, not just a notice of a report publication. Therefore, the correct classification is POS with high confidence.
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024 年半年度报告摘要" which translates to "2024 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and net assets for the half-year period. It also includes extensive management discussion on business operations, R&D progress, production updates, shareholder information, and patent authorizations. The length of the document (9306 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim report rather than a brief announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.